SCHEMBL23387266

SCHEMBL23387266

O=C(Cc1ccc(C2CC2)cc1)NC1CN(c2ccc(C(F)(F)F)nc2)CC12CC2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CACNA1G O43497 1/20 0.40
▸ CACNA1H O95180 1/20 0.40
▸ CACNA1I Q9P0X4 1/20 0.40
▸ ENPP2 Q13822 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ DGAT1 O75907 1/20 0.38
▸ CRACR2A Q9BSW2 1/20 0.38
▸ FPR2 P25090 6/20 0.38
▸ CHRM4 P08173 4/20 0.38
▸ TGM2 P21980 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.37
▸ FPR1 P21462 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ CSF1R P07333 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ GRIA2 P42262 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23387263 1.00 CACNA1G (0.40) CACNA1GCACNA1HCACNA1IENPP2CCNC
SCHEMBL23387160 0.83 CACNA1G (0.38) CACNA1GCACNA1HCACNA1ICRACR2A
SCHEMBL23387156 0.83 CACNA1G (0.38) CACNA1GCACNA1HCACNA1ICRACR2A
SCHEMBL21624698 0.82 CCNC (0.54) CACNA1GCACNA1HCACNA1ICCNCCDK8
SCHEMBL21624701 0.82 CCNC (0.54) CACNA1GCACNA1HCACNA1ICCNCCDK8
SCHEMBL23387324 0.81 CCNC (0.43) CCNCCDK8FPR2CHRM4USP30
SCHEMBL23387325 0.81 CCNC (0.43) CCNCCDK8FPR2CHRM4USP30
SCHEMBL23387182 0.81 KCNH2 (0.42) CACNA1GCACNA1HCACNA1ICSF1RCYP3A4
SCHEMBL23387185 0.81 KCNH2 (0.42) CACNA1GCACNA1HCACNA1ICSF1RCYP3A4
SCHEMBL22499808 0.80 CCNC (0.48) CACNA1GCACNA1HCACNA1ICCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 — — US claimed
EP-3825303-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nippon Chemiphar Co., Ltd. (JP) 2021-05-26 — — EP claimed
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 — — US disclosed
EP-3950059-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS Nippon Chemiphar Co., Ltd. (JP) 2022-02-09 — — EP disclosed
EP-3825303-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nippon Chemiphar Co., Ltd. (JP) 2021-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1H CACNA1G 2/4885CACNA1H 3/4885CACNA1I 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback